Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s (NOVO: N) bid to become the GLP-1 company of choice for payers and prescribers.
Adding to earlier data in the important co-morbidity of cardiovascular disease, the latest results, published in Nature, show that the apparent protective effects of Wegovy (semaglutide) were achieved, regardless of whether patients lost weight.
The company has already shown that treatment with Wegovy led to a statistically-significant and superior reduction in major adverse cardiovascular events, a reduction of around a fifth compared to placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze